Anti-Cancer MAbS Market Report 2026

The anti-cancer mabs market size has grown strongly in recent years. It will grow from $71.25 billion in 2025 to $78.12 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rising global cancer incidence, clinical success of monoclonal antibodies, strong oncology r&d investment, regulatory approvals for biologics, increased survival outcomes in cancer treatment.

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $112.41 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to growth in personalized cancer medicine, expansion of biosimilar mAbs, rising oncology healthcare spending, advances in antibody engineering, increasing access to biologic therapies. Major trends in the forecast period include rising adoption of targeted immunotherapies, expansion of humanized and bispecific antibodies, growing use of combination cancer therapies, increasing focus on precision oncology, improved manufacturing scalability of mAbs.

The rising incidence of cancer worldwide is expected to drive the growth of the anticancer mAbs market in the coming years. Cancer is a collection of diseases characterized by uncontrolled cell growth with the potential to invade and damage healthy body tissues. The growing incidence of cancer is attributed to aging populations, lifestyle shifts, environmental factors, and improvements in diagnostic technologies that lead to higher detection rates. Anticancer monoclonal antibodies (mAbs) are engineered to attach to specific proteins on cancer cells, leveraging genetically modified versions of the immune system’s own antibodies to target and eliminate these cells; therefore, the rising prevalence of cancer boosts demand for the anticancer mAbs market. For example, in February 2024, according to the World Health Organization (WHO), a Switzerland-based United Nations agency, new cancer cases are projected to surpass 35 million by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer worldwide is fueling the expansion of the anticancer mAbs market.

Major companies operating in the anti-cancer monoclonal antibodies (mAbs) market are concentrating on developing innovative approaches, such as early-phase clinical trials, to advance new therapeutic candidates and enhance their competitive edge. Clinical trials are structured research studies conducted in human participants to assess the safety, dosage, and therapeutic efficacy of novel medical interventions, including targeted antibodies and radioimmunotherapies. For example, in April 2023, Y-mAbs Therapeutics Inc., a US-based clinical biopharmaceutical company, initiated a Phase I clinical trial evaluating GD2-SADA, a pre-targeted radioimmunotherapy intended for GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. The treatment employs a two-step mechanism in which the SADA protein first binds selectively to GD2-expressing tumor cells, followed by administration of the radioactive ligand 177Lu-DOTA, which attaches to the SADA protein to deliver targeted radiation, aiming to maximize tumor cell elimination while minimizing radiation exposure to healthy tissues.

In June 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.8 billion. This acquisition enhances Merck’s immunology portfolio by incorporating Prometheus’s lead candidate PRA023 (now MK-7240), a monoclonal antibody targeting TL1A, which plays a role in autoimmune conditions such as ulcerative colitis and Crohn’s disease. It also strengthens Merck’s pipeline with advanced biologics and facilitates expansion into precision immunology through Prometheus’s biomarker-driven development platform. Prometheus Biosciences Inc. is a US-based clinical-stage biotechnology company focused on developing monoclonal antibody therapies.

Major companies operating in the anti-cancer mabs market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, ADC Therapeutics, MacroGenics Inc., Zymeworks Inc.

North America was the largest region in the anti-cancer MAbS market in 2025. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-cancer mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported biologic manufacturing inputs, cell culture media, and specialized equipment used in the production of anti cancer monoclonal antibodies. These impacts are most significant in North America and Europe, where advanced biologics manufacturing depends on global supply networks. Rising tariff related expenses have placed pressure on production economics and pricing strategies for oncology biologics. This has influenced capacity planning and investment decisions among biopharmaceutical manufacturers. However, tariffs are also encouraging local biologics manufacturing, regional capacity expansion, and stronger biopharmaceutical supply chain development over the long term.

The anti-cancer mabs market research report is one of a series of new reports that provides anti-cancer mabs market statistics, including anti-cancer mabs industry global market size, regional shares, competitors with a anti-cancer mabs market share, detailed anti-cancer mabs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer mabs industry. This anti-cancer mabs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anticancer monoclonal antibodies are antibodies utilized in monoclonal antibody therapy to specifically target and eliminate cancer cells. These antibodies are designed to attach to particular proteins or chemicals present on the surface of cancer cells, thereby inhibiting their growth and preventing their spread.

The main types of anti-cancer mAbs include murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine antibodies are a type of monoclonal antibody (mAb) that are artificially produced as an exact copy of a single antibody, generated by a single B cell, and derived from mice or rats. They function by binding to a specific antigen. These antibodies are applied in the treatment of various cancers such as blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, and others, and are utilized in hospitals, research institutes, and similar settings.

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.